Risks
4 risks
Risk Intelligence
High debt and stretched receivables
View Risks →
Indoco Remedies Limited — Q4 FY26
Indoco Remedies reported a strong Q4 FY26 with consolidated revenue of ₹456 crore, up 18.8% YoY, driven by a 94.6% surge in international formulations, particularly in regulated markets (US +77.5%, Europe +68.7%) and emerging markets (+134%).
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Indoco Remedies reported a strong Q4 FY26 with consolidated revenue of ₹456 crore, up 18.8% YoY, driven by a 94.6% surge in international formulations, particularly in regulated markets (US +77.5%, Europe +68.7%) and emerging markets (+134%). Domestic formulation revenue declined 6% due to muted seasonal demand for anti-infectives and respiratory products, though prescription growth remained healthy. EBITDA margin improved to 10.9% (vs -0.2% last year) on operating leverage. Management guided for continued international momentum, with US liquid oral approvals and European contract manufacturing scaling up. Key risks include elevated debt (₹960 crore consolidated), stretched receivables from export growth, and the unresolved sterile plant issue limiting future US approvals.
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
International Formulation Revenue Growth
₹2,147M
+94.6% YoY
International formulations grew 94.6% YoY to ₹2,147 million, driven by strong performance across regulated and emerging markets.
US Business Revenue
₹546M
+77.5% YoY
US business grew 77.5% YoY to ₹546 million, aided by solid oral sales and second-site transfers for sterile products.
Emerging Markets Revenue
₹746M
+134% YoY
Emerging markets revenue surged 134% YoY to ₹746 million, led by field force expansion in East and West Africa.
Debt Repayment Commitment
₹140Cr
per year for next 3 years
Management committed to repaying ~₹140 crore annually over the next three years, targeting debt reduction.
Fast read
Guidance and risk preview
Management committed to repaying approximately ₹140 crore each year for the next three years, with potential prepayment.
Consolidated debt stands at ~₹960 crore, with receivables growing 45% YoY due to longer credit periods in emerging markets, straining cash flow.
View Risks →